Clinical trial · Observational
ExoDx Prostate Evaluation in Active Surveillance Patient Population
NCT05572099CI-TRIAL-00061298unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to test whether the ExoDx Prostate test add value in biopsy decision making to patients with prostate cancer on an active surveillance regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ExoDx Prostate | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Develop and evaluate risk-based scoring using the ExoDx Prostate test.
- timeFrame
- 1yr after last enrolled patient
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Male, 45+ years of age diagnosed with low-grade or favorable-intermediate prostate cancer and on an active surveillance regimen Exclusion Criteria: * Clinical symptoms of urinary tract infection at time of enrollment. * History of invasive treatment for benign prostatic hypertrophy with in 6 months of enrollment. * Known hepatitis or HIV * History of concurrent renal/bladder tumors
References
Publications (0)
Data not yet available
No reference posted for this study.